Approximately 100 million people worldwide are affected by M. Tuberculosis (Mtb), a contagious disease which causes death in humans and is considered to be quite deadly throughout the world (about 1.5 million deaths annually). Approximately 20% of these deaths are attributed to strains that are resistant to drugs for combating TB. This situation is further exacerbated by the spread of HIV/AIDS worldwide. Consequently, it is important to identify and fully develop new therapeutic targets in the fight against Mtb. Treatment, over the past decades, has essentially shown limited efficacy and/or undesirable side effects. Due to the high mortality rate of TB and the increase in strains that are resistant to drugs, the exploration and synthesis of novel and more effective treatment regimens with less undesirable side effects is imperative.

Two approaches are being considered a) chemical modification of currently used drugs with the intention of reducing the time for treatment and b) the exploration and synthesis of new and novel compounds which are more effective. In this regard, several transition metal complexes have been identified as potential chemotherapeutic agents against TB and HIV. Recently, the focus has been on the use of platinum and ruthenium complexes as alternative metal-based antimycobacterial and anti-HIV therapeutic agents.

This minireview focuses on recent developments in the use of Pt and Ru complexes as novel therapeutic agents for TB and HIV.

全世界约有1亿人患有结核分枝杆菌（Mtb），这是一种会传染给人类的传染性疾病，在全世界被认为是致命的（每年约150万人死亡）。这些死亡中约有20％归因于抗结核药物的菌株。艾滋病毒/艾滋病在世界范围内的传播进一步加剧了这种情况。因此，重要的是在对抗Mtb的过程中确定并充分开发新的治疗靶标。在过去的几十年中，治疗基本上显示出有限的功效和/或不良的副作用。由于结核病的高死亡率和耐药菌株的增加，必须探索和合成具有更少不良副作用的新颖，更有效的治疗方案。

正在考虑两种方法：a）对目前使用的药物进行化学修饰，以减少治疗时间； b）探索和合成更有效的新化合物。在这方面，已鉴定出几种过渡金属络合物作为抗结核和艾滋病毒的潜在化学治疗剂。近来，焦点已经集中在使用铂和钌配合物作为替代的基于金属的抗分枝杆菌和抗HIV治疗剂上。

这份小型综述的重点是将Pt和Ru复合物用作结核病和HIV的新型治疗剂的最新进展。